Trial Profile
A Phase 1 Study of TRAIL-DR5 Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 8273 (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2020 Planned End Date changed from 1 Dec 2019 to 21 Mar 2024.
- 08 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.